04693124001
Roche
cOmplete™, Mini Protease Inhibitor Cocktail
Tablets provided in EASYpacks
Sinónimos:
protease inhibitor
Iniciar sesiónpara Ver la Fijación de precios por contrato y de la organización
About This Item
UNSPSC Code:
12352204
NACRES:
NA.21
Productos recomendados
form
tablet
packaging
pack of 30 tablets (individually packed in foil blister packs)
manufacturer/tradename
Roche
solubility
aqueous buffer: soluble
water: soluble
storage temp.
2-8°C
General description
cOmplete, Mini Protease Inhibitor Tablets, inhibit a broad spectrum of serine, cysteine and metalloproteases, as well as calpains. Due to the optimized composition of the tablets, they show excellent inhibition effects, and are well suited for the protection of proteins isolated from animal tissues, plants, yeast, and bacteria.
cOmplete, Mini, contains EDTA and both irreversible and reversible protease inhibitors.
cOmplete, Mini, contains EDTA and both irreversible and reversible protease inhibitors.
Specificity
For the inhibition of serine, cysteine, and metalloproteases in bacterial, mammalian, yeast, and plant cell extracts.
Application
cOmplete™, Mini Protease Inhibitor Cocktail has been used as a component in
- mammalian-protein extraction reagent (M-PER) for lysis of glioma stem cells (GSCs)
- sodium dodecyl sulphate-tris buffered saline (SDS-TBS) for the homogenisation of brain tissues
- radioimmunoprecipitation assay (RIPA) buffer for lysis of human embryonic stem cells (hESCs)
cOmplete™, Mini, is used for the inhibition of serine, cysteine, and metalloproteases in bacterial, mammalian, yeast, and plant cell extracts.
cOmplete, Mini, contains both reversible and irreversible protease inhibitors. Therefore, we recommend the addition of cOmplete, Mini, to all stock buffers and solutions normally protected with protease inhibitors, and not just during the initial purification steps.
cOmplete, Mini, contains EDTA (1 tablet yields a 1 mM EDTA solution in 10 ml). Therefore, the extraction buffer should not contain divalent cations like Ca2+, Mg2+, or Mn2+, otherwise the inhibition of the metalloproteases might be incomplete. If the protein of interest will be purified by IMAC (Immobilized Metal Affinity Chromatography), for example, Poly-His-tagged recombinant proteins, EDTA has to be eliminated (e.g., by dialysis) prior to the chromatography.
Alternatively, the product cOmplete, Mini, EDTA-free, can be used. These tablets are identical to cOmplete, Mini, with the exception that no EDTA or other chelating agent is present.
cOmplete, Mini Tablets, inhibit proteolytic activity in small extraction volumes (up to 10 ml). If you are working with a larger volume (up to 50 ml), we recommend to use a different cOmplete product. The composition of the cOmplete Tablet is identical to the cOmplete, Mini Tablet, therefore, comparable results are achieved with both product types.
cOmplete, Mini, contains both reversible and irreversible protease inhibitors. Therefore, we recommend the addition of cOmplete, Mini, to all stock buffers and solutions normally protected with protease inhibitors, and not just during the initial purification steps.
cOmplete, Mini, contains EDTA (1 tablet yields a 1 mM EDTA solution in 10 ml). Therefore, the extraction buffer should not contain divalent cations like Ca2+, Mg2+, or Mn2+, otherwise the inhibition of the metalloproteases might be incomplete. If the protein of interest will be purified by IMAC (Immobilized Metal Affinity Chromatography), for example, Poly-His-tagged recombinant proteins, EDTA has to be eliminated (e.g., by dialysis) prior to the chromatography.
Alternatively, the product cOmplete, Mini, EDTA-free, can be used. These tablets are identical to cOmplete, Mini, with the exception that no EDTA or other chelating agent is present.
cOmplete, Mini Tablets, inhibit proteolytic activity in small extraction volumes (up to 10 ml). If you are working with a larger volume (up to 50 ml), we recommend to use a different cOmplete product. The composition of the cOmplete Tablet is identical to the cOmplete, Mini Tablet, therefore, comparable results are achieved with both product types.
Features and Benefits
- Convenience: Simply push the quick-dissolving tablet through the foil packaging of the EASYpack into your buffer.
- Complete protection: Instantly protect your proteins against a broad range of proteases (see Table 1).
- Flexible: Protect proteins in extracts from almost any tissue or cell, including animals, plants, yeast, bacteria, or fungi.
- Safe: Choose non-toxic inhibitors that pose no risk to you or those around you.
- Suitable for IMAC purification: Purify poly-histidine tagged proteins with cOmplete His-Tag Purification Resin.
Packaging
30 individually packed cOmplete Protease Inhibitor Cocktail Tablets in foil blisters. Each tablet is sufficient for a volume of 10 ml solution.
Components
Proprietary mixture of several protease inhibitors with broad inhibitory specificity.
Quality
Performance-tested with pancreas extract.
Physical form
Tablets in foil blister packs
Preparation Note
Working concentration: 1 tablet per 10 ml extraction solution
Preparation of Working Solution:
Carefully push the tablet through the foil packaging using the base of your thumb (not fingernail) to prevent breakage of tablets.
One cOmplete Mini tablet is sufficient for the inhibition of the proteolytic activity in 10 ml extraction solution. When very high proteolytic activity is present, one tablet should be used for 7 ml extraction buffer. The tablets can be added directly to the extraction medium. Alternatively, a stock solution (7 X conc.) can be prepared.
Stock solution (7 X conc.):
Dissolve one cOmplete Mini tablet in 1.5 ml dist. water or in 1.5 ml 100 mM phosphate buffer, pH 7.0.
Storage conditions (working solution): The stock solution can be stored at 2 to 8 °C for 1 to 2 weeks, or at least 12 weeks at -15 to -25 °C.
Preparation of Working Solution:
Carefully push the tablet through the foil packaging using the base of your thumb (not fingernail) to prevent breakage of tablets.
One cOmplete Mini tablet is sufficient for the inhibition of the proteolytic activity in 10 ml extraction solution. When very high proteolytic activity is present, one tablet should be used for 7 ml extraction buffer. The tablets can be added directly to the extraction medium. Alternatively, a stock solution (7 X conc.) can be prepared.
Stock solution (7 X conc.):
Dissolve one cOmplete Mini tablet in 1.5 ml dist. water or in 1.5 ml 100 mM phosphate buffer, pH 7.0.
Storage conditions (working solution): The stock solution can be stored at 2 to 8 °C for 1 to 2 weeks, or at least 12 weeks at -15 to -25 °C.
Reconstitution
Soluble in aqueous buffers, or add directly to extraction media. Alternatively, prepare 7x stock solutions in 1.5 ml water or 100 mM phosphate buffer, pH 7.0. Stock solution is stable for 1-2 weeks at 2 to 8 °C or at least 12 weeks at -15 to -25 °C; can be used in thiol-containing solutions at 15 to 25 °C.
Other Notes
For life science research only. Not for use in diagnostic procedures.
Legal Information
cOmplete is a trademark of Roche
Related product
Referencia del producto
Descripción
Precios
signalword
Warning-Warning
Hazard Classifications
Eye Irrit. 2 - Skin Irrit. 2
Storage Class
11 - Combustible Solids
wgk_germany
WGK 2
flash_point_f
does not flash
flash_point_c
does not flash
Certificados de análisis (COA)
Busque Certificados de análisis (COA) introduciendo el número de lote del producto. Los números de lote se encuentran en la etiqueta del producto después de las palabras «Lot» o «Batch»
¿Ya tiene este producto?
Encuentre la documentación para los productos que ha comprado recientemente en la Biblioteca de documentos.
Los clientes también vieron
The antibiotic clofoctol suppresses glioma stem cell proliferation by activating KLF13
Hu Y, et al.
The Journal of Clinical Investigation, 129(8) (2019)
Wenping Ma et al.
Neuroscience bulletin, 36(4), 359-371 (2019-10-28)
Gliomas are the most commonly occurring tumors of the central nervous system. Glioblastoma multiforme (GBM) is the most malignant and aggressive brain cancer in adults. Further understanding of the mechanisms underlying the aggressive nature of GBM is urgently needed. Here
Yu Sun et al.
Molecular medicine reports, 24(5) (2021-09-10)
Glioblastoma (GBM) is one of the most common and malignant types of primary cancer in the central nervous system; however, the clinical outcomes of patients with GBM remain poor. Circular RNAs (circRNAs) have been revealed to serve important roles in
Characterization of the 18 kda translocator protein (tspo) expression in post-mortem normal and alzheimer's disease brains
Gui Y, et al.
Brain Pathology, 1-14 (2019)
Jakob Triebel et al.
European journal of endocrinology, 161(2), 345-353 (2009-05-30)
In vitro experiments and in vivo studies on rodents demonstrate that N-terminal 14, 15, 16, 17, and 18 kDa fragments prolactin-related vasoinhibin (PRL-V) of human PRL are natural inhibitors of neovascularization in the retina and elsewhere. These N-terminal PRL fragments
Nuestro equipo de científicos tiene experiencia en todas las áreas de investigación: Ciencias de la vida, Ciencia de los materiales, Síntesis química, Cromatografía, Analítica y muchas otras.
Póngase en contacto con el Servicio técnico